Fractyl has the GUTS: Obe­si­ty and di­a­betes biotech charts $99M IPO

Fractyl Health is at­tempt­ing to ride the waves cre­at­ed by last week’s suc­cess­ful biotech IPOs for can­cer drug­mak­ers CG On­col­o­gy and Ar­riVent Bio­phar­ma.

The car­diometa­bol­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER